2021
DOI: 10.1002/pbc.29211
|View full text |Cite
|
Sign up to set email alerts
|

Nintedanib for treatment of progressive interstitial lung disease after peripheral blood stem cell transplantation in a patient with recurrent acute lymphoblastic leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 9 publications
0
1
0
Order By: Relevance
“…Sorafenib works by stopping the progression of cancer and blocking the therapeutic replication of potentially malignant cells [ 49 ]. Nintedanib is a small-molecule kinase inhibitor that competitively inhibits both non-receptor tyrosine kinases and receptor tyrosine kinases, and these inhibitory effects increase fibroblast proliferation, migration, and transformation [ 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…Sorafenib works by stopping the progression of cancer and blocking the therapeutic replication of potentially malignant cells [ 49 ]. Nintedanib is a small-molecule kinase inhibitor that competitively inhibits both non-receptor tyrosine kinases and receptor tyrosine kinases, and these inhibitory effects increase fibroblast proliferation, migration, and transformation [ 50 ].…”
Section: Discussionmentioning
confidence: 99%